2563866-80-6

2563866-80-6 structure
2563866-80-6 structure
  • Name: Indinavir sulfate ethanolate
  • Chemical Name: Indinavir sulfate ethanolate
  • CAS Number: 2563866-80-6
  • Molecular Formula: C38H55N5O9S
  • Molecular Weight: 757.94
  • Catalog: Signaling Pathways Anti-infection HIV
  • Create Date: 2022-08-31 11:45:57
  • Modify Date: 2024-01-12 23:55:56
  • Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CLpro inhibitor[1][2][3][4].

Name Indinavir sulfate ethanolate
Description Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CLpro inhibitor[1][2][3][4].
Related Catalog
Target

HIV-1

MMP-2

In Vitro Indinavir sulfate ethanolate (0-50 µM; 18 h) blocks lymphocyte cell cycle in G0/G1 phase in PBMCs cells and impairs lymphoproliferative responses[1]. Indinavir sulfate ethanolate (40 µM-40 nM; 5 days) inhibits cell invasion and (40 µM-40 nM; 48 h) MMPs-2 activation of the Huh7 and SK-HEP-1 hepatocarcinoma cells in vitro[2]. Cell Viability Assay[1] Cell Line: PBMCs (from healthy and HIV-infected volunteers) Concentration: 0-50 µM Incubation Time: 18 h (pretreatment; stimulation with anti-CD3 for an additional 48 hours) Result: Blocked anti-CD3-induced cell-cycle progression in a dose-dependent manner. Resulted in dose-dependent reduction of lymphoproliferative responses. Cell Invasion Assay[2] Cell Line: Huh7 and SK-HEP-1 cells Concentration: 40 µM-40 nM Incubation Time: 5 days Result: Reduced ability to invade an in vitro constituted extracellular matrix for both cell lines treated compared with the untreated cells. Western Blot Analysis[2] Cell Line: Huh7 and SK-HEP-1 cells Concentration: 40 µM-40 nM Incubation Time: 48 h Result: Blocked the conversion of latent MMP-2 to its 62/64-kDa active form.
In Vivo Indinavir sulfate ethanolate (70 mg/kg; i.g.; once a day for 3 weeks) inhibits the growth of hepatocarcinoma cells in vivo[2]. Animal Model: Nude mice(s.c. into Huh7 and SK-HEP-1 cells)[2]. Dosage: 70 mg/kg Administration: Oral gavage; once a day for 3 weeks Result: Delaied the growth of s.c. implanted hepatocarcinoma xenografts in nude mice compared with placebo.
References

[1]. Chavan S, et al. The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood. 2001 Jul 15;98(2):383-9.

[2]. Esposito V, et al. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res. 2006 Apr 15;12(8):2634-9.

[3]. Liu F, et al. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol. 2005 Dec 9;354(4):789-800.

[4]. Hall DC Jr, et al. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 May-Jun;35:101646.

Molecular Formula C38H55N5O9S
Molecular Weight 757.94
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.